chrisvoncsefalvay/vaers-outcomes huggingface dataset:
had a covid 19 infection and she is due to her second dose of the Pfizer covid vaccine; had a covid 19 infection and she is due to her second dose of the Pfizer covid vaccine; This is a spontaneous report from a contactable consumer or other non hcp. A female patient of an unspecified age received bnt162b2 (BNT162B2, Solution for injection), dose 1 via an unspecified route of administration on 09Mar2021 (Batch/Lot number was not reported) as SINGLE DOSE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. On an unknown date, the patient underwent lab tests and procedures which included covid 19 test which gives positive covid 19 infection, and she is due to her second dose of the covid vaccine and  she wonders if she can have it.The event was considered serious as medically significant.The outcome of the event was unknown.  Information on the lot/batch number has been requested.
I received the shingles vaccine and within 3 hours developed pain in both legs including burning, numbness sensitive to touch. Went to ER 4 days later, treated with Vicodin for pain. Still feel nite pain 11 days later but less.
This is a spontaneous report from a contactable consumer (Patient). A 35-year-old male patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration, administered in Arm Left on 19May2021 22:30 (Batch/Lot Number: EW0177) as single dose for covid-19 immunisation at the age of 35-year-old.  Medical history included allergies to Penicillin, Cipro. There were no concomitant medications. On 14May2021 18:00 (as reported), the patient experienced Sleepwalking for 6 hours straight. Hallucinations. Severe sweating, heart racing, hot flash. The events were recovered without treatment. The patient was not COVID prior vaccination and hasn't been tested post vaccination.
Arm/shoulder hurt times 2 1/2 months. Gradually getting better. Still not full range of motion without pain.
Reaction to vaccines (R) arm. 2 reactions from vaccines. (1) 9 1/2 cm x 12 cm - red, warm, swollen - actually hard where pt. had KINRIX vaccine. (2) 3 1/2 cm x 2 cm - slightly less red but warm and swollen at site of Varicella injection.
Patient given regular Moderna booster instead of Bi valent booster as ordered. This vaccination made this a fifth dose of booster dosing of original Moderna instead of getting the dose of Bi valent booster.
The next day I have severe acid reflux and I don't have that normally; Severe runny nose; achey; chills; really bad sore arm; This is a spontaneous report from a contactable other health care professional. A 50-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection, Lot number: El9265, Expiration date: Unknown) via an intramuscular route of administration in right arm on 02Feb2021 (at the age of 50-year-old) as UNKNOWN, SINGLE DOSE for Covid-19 immunisation. The patient medical history was not reported. No known allergies were reported. No known allergies were reported. The patient concomitant medications were not reported. Patient did not receive any other vaccines within 4 weeks prior to covid vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 02Feb2021 at 14:45, the patient had experienced severe runny nose, achey, and chills, really bad sore arm and on 03Feb2021, next day patient had severe acid reflux and don't have that normally. Patient did not receive any treatment for the events. The outcome of events was recovering at the time of reporting.  Follow-up attempts are completed. No further information is expected.
I ordered a monovalent pfizer covid vaccine.  My MA accidentally gave a bivalent covid vaccine.
Couldn't feel arm; Couldn't feel arm and had no range in motion; Pain in upper shoulder area by his neck; Thinks the administration was done incorrectly; Aching in legs as if he was getting sick; Aching in legs as if he was getting sick; Pain in upper shoulder area by his neck; A spontaneous report was received from a nurse concerning her son, who was a 44-year-old male patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced couldn't feel arm and had no range in motion (hypoaesthesia, joint range of motion decreased), pain in upper shoulder area by the neck (arthralgia, neck pain), thinks administration was done incorrectly (product administration error), and aching in legs as if was getting sick (arthralgia, malaise).  The patient's medical history was not provided.  Concomitant medication included escitalopram.  On 04 Feb 2021, on the same day as the onset of the events, the patient received their first of two planned doses of mRNA-1273 (batch number: 030L20A) in the left arm for prophylaxis of COVID-19 infection.  On 04 Feb 2021, a couple of hours after the vaccination, the patient couldn't feel his arm and he had no range in motion.  He also had pain in his upper shoulder area by his neck.  The reporter thought the administration was done incorrectly but she "wasn't there to conform 100%."  At night on 04 Feb 2021 and 05 Feb 2021, the patient had aching in his legs "as if he was getting sick."  Treatment for the events included ibuprofen which helped, and the patient was feeling better at the time of this report.  Action taken with mRNA-1273 in response to the events was not reported.   The events, couldn't feel arm and had no range in motion, pain in upper shoulder area by the neck, and aching in legs as if was getting sick, were considered recovering/resolving at the time of this report.  The event, thinks administration was done incorrectly, was considered recovered/resolved on 04 Feb 2021.; Reporter's Comments: This case concerns a 44-year-old male who experienced NS unexpected events of hypoaesthesia, joint range of motion decreased, arthralgia, neck pain, product administration error, malaise, and NS expected arthralgia.  The events occurred 1 day after the first dose of mRNA-1273. Events resolved. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-012275: US-MODERNATX, INC.-MOD-2021-012263:
It was reported that a pt rec'd a TD adult vaccination on 4/7/00. Reportedly after that vaccination the pt experienced swelling and redness of the L arm at the injection site. From correspondence rec'd on 5/5/00, it was reported that the pt recovered from this experience. Additional pt, vaccine and responsible physician information was also provided.
chilling, achiness, nausea; inability to open hands, diarrhea; DPH;
Faint pale/pink coloration superiorly around upper vaccine site; inverted equilateral triangle with ~3 cm side over lower vaccine site that is indurated and warm to touch, small amount of ecchymosis along bottom border of upper tricep; entire lesion is 8 cm long and 4 cm wide. Palpably firm inner upper tricep with no color change or bruising.
The morning after the 2nd dose, I had a massive migraine, chills and body aches that lasted 24 hours. In addition I have a reaction on injection side. My arm is warm to the touch, swollen, and red.
Symptoms immediately following the vaccine on Wednesday; tachycardia, shortness of breath, dizziness.   Symptoms the following day on Thursday; tachycardia, shortness of breath, weakness, fatigue.   Symptoms on Friday; tachycardia, shortness of breath, weakness, fatigue, diarrhea, cough, loss of control of extremities, debilitating headache, nausea, dizziness.   Symptoms on Saturday; chills, tachycardia, shortness of breath, weakness, fatigue, diarrhea, cough, loss of control of extremities, debilitating headache, nausea, dizziness, blurred vision, sensitivity to lighten and sound, sore throat, stuffy nose, ringing in ears.   Symptoms on Sunday to current 2/3/21 tachycardia, shortness of breath, weakness, fatigue, diarrhea, cough, loss of control of extremities, debilitating headache, nausea, dizziness, blurred vision, sensitivity to lighten and sound, sore throat, stuffy nose, ringing in ears.
left arm bright red rash, started after vaccine, improved then restarted at date stated above. No pain or itching. Watched for 2 days with no treatment, slight spreading but redness improved to lighter pink. Patient instructed to call when resolved or if worsening.
Subsequently post vax, the pt experienced weakness in the forearm of the arm where the vaccine was administered. Unspecified medical attention was sought.
Second dose was given more than 35 days after first dose; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose was given more than 35 days after first dose) in a 45-year-old male patient who received mRNA-1273 (Spikevax) (batch nos. 013L20A and 006M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 22-Jan-2021, the patient received first dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On 09-Mar-2021, received second dose of mRNA-1273 (Spikevax) (Intramuscular) dosage was changed to 1 dosage form. On 09-Mar-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose was given more than 35 days after first dose). On 09-Mar-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose was given more than 35 days after first dose) had resolved.        For mRNA-1273 (Spikevax) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant and treatment medication were reported.    This case was linked to MOD-2021-385925 (Patient Link).
This case involves an unknown age female patient who experienced got sick and flu while receiving vaccine INFLUENZA VACCINE. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via unknown route in unknown administration site for prophylactic vaccination. On an unknown date the patient developed a non-serious event "got sick" (illness) (unknown latency) following the administration of INFLUENZA VACCINE. On an unknown date the patient developed a non-serious event "flu" (influenza) (unknown latency) following the administration of INFLUENZA VACCINE. It was reported "several years ago. got sick, went to doctor. Diagnosed with flu. No I cannot have it, I took the shot. they said it is only good for 60 days or so". Action taken with INFLUENZA VACCINE (INFLUENZA VACCINE) was not applicable. It was not reported if the patient received a corrective treatment for the events (got sick, flu). At time of reporting, the outcome was Unknown for the event got sick and was Unknown for the event flu.
12/4/21-Headache and vomiting two times. Subsided by 12/5/21.  12/14/21-Vomiting, abdominal pain started in the middle of the night. Still having abdominal pain currently(12/15/21).
loss of smell after 2nd shot. consistent issues since that second series; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 30-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 25Feb2021 10:45 (Lot number: EN6198) at the age of 30 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "HYPOTHYROID" (unspecified if ongoing); "PCOS" (unspecified if ongoing); "Allergies: Penicillin" (unspecified if ongoing); "Allergies: Some Cephalosporins" (unspecified if ongoing). Concomitant medication(s) included: WILD YAMS; MACA [LEPIDIUM MEYENII]; SOYA LECITHIN. Past drug history included: Amoxicillan, reaction(s): "Allergies: Amoxicillin"; Doxycycline, reaction(s): "Allergies: Doxycycline". Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: EN9581, Location of injection: Arm Left, Vaccine Administration Time: 04:30 PM), administration date: 29Jan2021, when the patient was 30 years old, for Covid-19 immunization. The following information was reported: ANOSMIA (non-serious) with onset 25Feb2021, outcome "not recovered", described as "loss of smell after 2nd shot. consistent issues since that second series". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of anosmia.  Additional information: loss of smell after 2nd shot. consistent issues since that second series. never recovered prior enhanced smell since then. Patient received Nasal Spray as treatment. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was tested since the vaccination. The patient was not diagnosed with COVID-19 prior to vaccination.   Follow-Up: Follow-up attempts are completed. No further information is expected.
Generalized joint pain, abdominal cramping without nausea or diarrhea. Lasted 12 hours. Took 2 doses of Tylenol .
Breakthrough case admission after 3 vaccines  Moderna 3/24/21 lot# 038A21A;  Moderna 4/21/21 lot# 040B21A;  Moderna 1/19/22 lot# 066H21A
rash for more than 2 months post vaccination; joint pain for more than 2 months post vaccination; arm pain for more than 2 months post vaccination; This non-serious case was reported by a physician via sales rep and described the occurrence of rash in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced rash (Verbatim: rash for more than 2 months post vaccination), joint pain (Verbatim: joint pain for more than 2 months post vaccination) and pain in arm (Verbatim: arm pain for more than 2 months post vaccination).  The patient was treated with steroids nos (Steroids) and nsaid's. The outcome of the rash, joint pain and pain in arm were unknown.   It was unknown if the reporter considered the rash, joint pain and pain in arm to be related to Shingrix.     It was unknown if the company considered the rash, joint pain and pain in arm to be related to Shingrix.   Additional Information: GSK Receipt date: 08-SEP-2023  A reporter reported that symptoms of his patient was experiencing rash, joint pain and arm pain for more than 2 months post vaccination with Shingrix.  The patient was treated with oral steroids with some success, but NSAIDS were unsuccessful.  The reporter consented to follow up.
I1st day after vaccine - initial onset of headache advancing to full headache and face pain, fatigue, mild pain at site of injection. 2nd day - severe headache, face pain, body ache, difficulty walking, nausea, vomiting, pain at shot site in left arm, chills, mild fever, unable to sleep due to body and face pain, racing thoughts, rash started that night. 3rd day - continued headache and face pain, body ache, pain at short site, rash spread down arms, across stomach and back, spread down legs as far as knees, and up across chest to neck.  By end of day racing thoughts had calmed. 4th day - headache and face pain subsided, body ache cleared, rash subsided by nighttime.
About 12 hours after, had a fever, body aches and tired. I took ibuprofen and that helped with the symptoms. These symptoms lasted about 24 hours.
Approximately 7 days after initial dose of MMR (5/16/06), patient complained of pain in neck, jaw and ear on right side. Symptoms gradually subsided; no fever, rash, lymphadenopathy or other objective findings. No treatment rendered. Utilized over-the-counter pain reliever.   Approximately 21 days after second dose of MMR (7/6/06), complained of same symptoms listed above, however, indicated pain was more severe. Again, no fever, rash, lymphadenopathy or other objective findings. Evaluated by personal physician ~ no physical findings. According to paitent, physician indicated possible allergies or subclinical case of shingles. As of this date, symptoms have completely subsided.
One week, post vax, site erythemic induration and area measured in size to about 8cm in diameter, was very itchy and warm to touch. Rx'd Biaxin 500 mg BID x 7 days, Benadryl cream, Zyrtec 10mg and ice pack. Vital signs on 5/15/01, BP 172/100; HR-64; Afebrile; RR-16.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in an 18-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Jan-2021 at 9:58 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 07-Jan-2021 at 9:58 AM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). In 2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 18.88.  Concomitant products were not provided.  On 07-Jan-2021, Excursion time and temperature were 09AM: 34 and 10 AM: 34 respectively. total doses given for the day was 96, condition of vaccine prior to administration was not frozen, vaccine was moved to fridge on 05-Jan-2021 and vial was moved to clinic on 07-Jan-2021. 06 vials were sent to clinic. Vaccine BUD date was 27-Jan-2021. The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour.  After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  It was reported that the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks in 2021. The HCP explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 and half hour approximately, when the temperature data logger registered 34 or 35 degree F.  Treatment medications were not reported.
No additional adverse events reported; improperly stored vaccines may have been administered to patients; This spontaneous report has been received from a nurse, referring to a patient of unknown gender and age. Information about the patient's pertinent medical history, concurrent conditions, and previous drugs reactions or allergies were not provided.  On 08-JAN-2020, the patient was vaccinated with an improperly stored (product storage error) hepatitis a vaccine, inactivated (VAQTA), (Therapy type: Digital Data Logger), lot number S025258 and expiration date 05-NOV-2020 for prophylaxis (strength, dose, dose number, frequency, route of administration, and anatomical location, were not provided).  The vaccine was stored at a temperature above 47 degree Fahrenheit (47.1 Fahrenheit), for a timeframe of 8 to 16 minutes, with no previous temperature excursion. The call was due to a Digital Data Logger.  No additional adverse events were reported.  This case is one of several cases from the same reporter.; Sender's Comments:  US-009507513-2001USA009007:
Left arm became very swollen. After doctor visit and chest ct scan, I was sent to a vascular doctor. H e diagnosed me with lymphedema. In treatment now.
This spontaneous report was received from a licensed practical nurse and refers to multiple unspecified patients of unknown age and gender. The patients' concurrent conditions and medical history were not provided. It was reported that improperly stored doses of RECOMBIVAX HB L044694, expiry date 04-FEB-2018, (dose and route were not reported), were given to unspecified multiple patients on 07-APR-2016. No adverse effects were reported. No product quality complain (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Pt reported to the ER due to lower extremity weakness, inability to ambulate. He denies hitting his head or any loss of consciousness. He states that he laid on the ground for 4 to 5 hours until he was able to move his leg to be able to stand up. Patient denies slurred speech, headache, dizziness, blurred vision. He denies chest pain, dizziness, shortness of breath, recent illness, fever, nausea, vomiting, diarrhea, abdominal pain, hematochezia, or melena. Pt did receive a flu vaccine October 3rd 2020 and the incident occurred Oct 7th 2020. Pt states this was the first time ever receiving the flu vaccine. patient denies any other illness, non smoker, non drinker.
Obstructive jaundice. Hospital admission was within 6 weeks of receiving the COVID vaccine.
Condition aggravated; Pain; Cramps; Stools watery; This spontaneous report received from a patient concerned a 63 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included: moderate to severe adult Crohn's disease, and moderate to severe ulcerative colitis. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on 01-APR-2021 for prophylactic vaccination. The batch number was not reported. The company is unable to perform follow-up to request batch/lot number.  Non-company suspect drugs included: adalimumab (form of admin unknown, subcutaneous, batch number was not reported) dose, frequency, and therapy dates were not reported, and dose, frequency, and therapy dates were not reported for moderate to severe adult crohn's disease, and moderate to severe ulcerative colitis. No concomitant medications were reported.  On 07-SEP-2021, the patient experienced condition aggravated. On 07-SEP-2021, the patient experienced pain. On 07-SEP-2021, the patient experienced cramps. On 07-SEP-2021, the patient experienced stools watery. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the condition aggravated, pain, stools watery and cramps was not reported. This report was non-serious.
Above Estimated start day only for tinnitus.....  other vacinnation.    rec'd   fluzone 11/9 &   2 part shingrix 11/19 & 2/8/22 developed tinnitus which has not subsided in several months. urgent care offered no assistance 2/2/2020. currently on steroid regiment for 25 days. ongoing  treatment